A heterodimer that combines CTLA-4 and a CD47 ligand can effectively deplete regulatory T cells inside tumors, allowing the immune system to fight off tumors without becoming overactive, according to a study published last week in Science Translational Medicine.

“By effectively removing these immune-suppressive cells inside tumors instead of in the whole body, the immune system can attack cancers without causing harmful autoimmune conditions,” said study leader Yang-Xin Fu, from UT Southwestern.

CTLA-4 and CD47 both reside on the surfaces of regulatory T cells (Tregs). These proteins, respectively, broadcast “eat me” and “don’t eat me” signals to phagocytes that keep Tregs in check, explained Dr. Fu. Various immunotherapies have sought to boost the “eat me” signal or decrease the “don’t eat me signal” to reduce Tregs in tumors. However, each strategy has drawbacks: Increasing the “eat me” signal has systemic effects that spur autoimmunity, while decreasing the “don’t eat me” signal has only shown promise for treating blood cancers, such as leukemias.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

Searching for a new way to deplete Tregs, the team created a heterodimer that simultaneously increases the “eat me” signal while blocking the “don’t eat me” signal to prompt phagocytes to consume those immune suppressive cells. When it was injected into mouse models of colon cancer, they found that it preferentially depleted Tregs in tumors without affecting those in the rest of the body. However, dosing these animals with equivalent, separate amounts of the “eat me” booster and “don’t eat me” blocker had systemic autoimmune side effects, suggesting that combining them within one molecule is key to reaching Tregs in tumors.

As the number of Tregs decreased with treatment, the animals’ tumors shrank significantly. This strategy also worked in mice carrying human lung cancer tumors, suggesting that it could be viable in human patients.

“In the past, there’s been no way to get rid of these suppressive Tregs without severe toxicity,” Dr. Fu said. “Our study suggests a way to this outcome.”